狂犬病免疫球蛋白研究与应用进展  

Progress on research and application of rabies immunoglobulin

作　　者：张信[1] 高标 陈启明[1] 吴定宇[1] 曹恒昌[1] 范昭[1] Zhang Xin;Gao Biao;Chen Qiming;Wu Dingyu;Cao Hengchang;Fan Zhao(Peking University Shenzhen Hospital,Emergency Department,Shenzhen 518034,China;Support Center of Teaching and Research,Naval Medical University,Shanghai 200433,China)

机构地区：[1]北京大学深圳医院急诊科,深圳市518034 [2]海军军医大学教研保障中心,上海200433

出　　处：《中华实验和临床感染病杂志（电子版）》2022年第4期229-233,共5页Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition)

基　　金：军队重点学科建设项目(No.HL21JD1206);上海海洋医学出版中心(培)(No.2018-775-2-1)。

摘　　要：狂犬病是一种危险的人畜共患疾病,仍可防不可治。暴露后免疫是预防狂犬病的唯一方法,严重的Ⅲ级暴露则需注射狂犬病免疫球蛋白。本文阐述狂犬病毒的结构和致病途径,回顾狂犬病免疫球蛋白应用现状以及抗狂犬病毒单克隆抗体的研发和生产,分析免疫球蛋白在狂犬病临床防治应用中存在的问题和策略进展,认为处于临床试验阶段的抗狂犬病毒单克隆抗体研发是未来临床应用的发展方向。Rabies is a dangerous zoonotic disease which is preventable but still untreatable.Immunization after exposure is the only measure to prevent rabies.For the severe levelⅢexposure,injection of rabies immunoglobulin is the important measure.This article summarizes the structure and pathogenesis of rabies virus,and reviews the application of rabies immunoglobulin,as well as the research and development of anti-rabies virus monoclonal antibody.The problems and progress in strategies in the clinical application of immunoglobulin for the prevention and treatment of rabies are also discussed.It suggests that the research and development of anti-rabies monoclonal antibody in the clinical trial stage is the future of clinical application.

关 键 词：狂犬病毒 暴露后免疫 狂犬病免疫球蛋白 人源单克隆抗体 

分 类 号：R512.99[医药卫生—内科学]